Rituximab Therapy for Refractory Dermatomyositis/Antisynthetase Syndrome

Medical Necessity and Standard of Care

The American College of Rheumatology recommends rituximab as adjunctive therapy for refractory dermatomyositis and inflammatory myopathies when patients have inadequate response to first-line therapies, with a strength of evidence rated as moderate to high 1, 2.
The Mayo Clinic treatment guidelines state that rituximab is becoming the alternative to cyclophosphamide in patients who have refractory idiopathic inflammatory myopathies or severe disease complications, based on high-quality evidence from clinical trials 3, 4.
The landmark Rituximab in Myositis study demonstrated that 83% of 200 pediatric and adult patients with refractory myositis showed favorable response and improvement throughout the 44-week trial, with a significant reduction in disease activity and improvement in quality of life 3, 5.

Standard rituximab induction dosing is 1000mg repeated at day 15 for initial treatment of refractory myositis, but extended dosing intervals are clinically appropriate and widely practiced for maintenance therapy in patients who have achieved remission, based on moderate-quality evidence from observational studies 3, 4, 5.

The treatment plan includes monitoring blood work every 3 months, which is appropriate for detecting cytopenias, infections, or disease flare, with a strength of evidence rated as high 3, 5.
Baseline immunoglobulin levels, hepatitis B and C screening, and tuberculosis screening should be confirmed prior to continued therapy, based on high-quality evidence from clinical guidelines 3, 5.

Maintaining disease remission with rituximab prevents muscle weakness, skin manifestations, joint disease, and potentially life-threatening pulmonary complications, with a significant improvement in quality of life and reduction in disease-related morbidity 1, 2.
The patient has achieved complete discontinuation of corticosteroids, eliminating risks of osteoporosis, diabetes, hypertension, infections, and other steroid-related complications, based on moderate-quality evidence from observational studies 2.